首页 | 本学科首页   官方微博 | 高级检索  
     

益生菌联合柳氮磺胺吡啶治疗炎症性肠病
引用本文:金志元. 益生菌联合柳氮磺胺吡啶治疗炎症性肠病[J]. 河北中西医结合杂志, 2008, 0(3): 333-334
作者姓名:金志元
作者单位:浙江省湖州市第一人民医院,浙江湖州313000
摘    要:目的评价益生菌联合柳氮磺胺吡啶对炎症性肠病的疗效。方法以本院92例住院和门诊的轻中度炎症性肠病患者为研究对象,随机分成2组,一组为益生菌联合柳氮磺胺吡啶治疗组,另一组为单用柳氮磺胺吡啶对照组。治疗8周后观察2组患者的主观评价、总体评价以及内镜复查的情况。结果治疗组患者的主观评价明显高于对照组(P〈0.05),临床缓解率也高于对照组(P〈0.05)。而内镜复查结果2组无显著性差异(P〉0.05)。结论益生菌对炎症性肠病的治疗是有效的和安全的。

关 键 词:益生菌  炎症性肠病  柳氮磺胺吡啶
文章编号:1008-8849(2008)03-0333-02
收稿时间:2007-06-30

Effect of combine probiotics with SASP on inflammatory bowel disease
Jin Zhiyuan. Effect of combine probiotics with SASP on inflammatory bowel disease[J]. , 2008, 0(3): 333-334
Authors:Jin Zhiyuan
Affiliation:Jin Zhiyuan(The First Hospital of Huzhou City,Huzhou 313000,Zhejiang,China)
Abstract:Objective It is to evaluate the therapeutic effect of probiotics and SASP in patients with inflammatory bowel disease(IBD).Methods This is a randomized clinical trial for 8 weeks.92 patients with mild-moderate IBD were divided into 2 groups,one treatment group was treated by probiotics and SASP,and another control group was treated by SASP only.The patients′ feeling,total estimation and condition of endoscopy were evaluated after the treatment.Results It was obviously well on patients′ feeling in treatment group than in control group(P〈0.05),and was also obviously well on clinical remission rate(P〈0.05),but there was no difference on condition of endoscopy(P〉0.05).Conclusion Probiotics can improve the clinical efficacy of inflammatory bowel disease,and was safe.
Keywords:probiotics  inflammatory bowel disease  SASP
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号